Semantic and Syntactic Computerized Analysis of Free Speech
NCT ID: NCT03525054
Last Updated: 2024-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2018-05-18
2028-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Linguistic Predictors of Outcomes in Psychosis
NCT05601050
Predicting Psychotic Relapse Using Speech-Based Early Detection
NCT06978894
Comparison of a Speech-Language Assessment Tool for Pragmatic and Discourse Skills in Schizophrenia Spectrum Disorders
NCT05742893
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
NCT03965598
Future Mental Projections in Schizophrenia
NCT03040505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
* If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
Exclusion Criteria
* Risk of self-harm or violence not compatible with outpatient treatment
* QI\<70 (WAIS)
* Neurological disorder or major health problem
* Impossibility to interrupt neuroleptic treatment for one week
* Refusal to participate
15 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest
Brest, , France
Meunier Sophie
Caen, , France
CH de SAINT ANNE
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sophie Meunier
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASESID (29BRC17.0198)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.